Colchicine trial revives cardiovascular quest to target inflammation

Hopes have been revived that the cheap anti-inflammatory drug colchicine may be re-purposed to reduce cardiovascular events in heart attack survivors. A large randomised controlled trial of low-dose colchicine in patients with a recent MI has shown it led to a significantly lower risk of ischaemic cardiovascular events than placebo.  In the Canadian COLCOT study, ...

Already a member?

Login to keep reading.

© 2021 the limbic